Notice 7 May 2025 compliance, california, dea, controlled substances, drug enforcement, medical regulation, physician

⚖️DEA Revokes Registration for Dr. Edmund Ayoub Jr. Due to Compliance Issues

The Drug Enforcement Administration has revoked the registration of Dr. Edmund Ayoub Jr. due to his cessation of authority to practice medicine in California, a prerequisite for handling controlled substances. The ruling highlights the implications of regulatory compliance for medical practitioners and their business operations in the healthcare sector.

Learn More
Notice 1 May 2025 regulatory compliance, pharmaceuticals, controlled substances, drug enforcement, business applications

💊DEA Notice on Importer Application for Controlled Substances

Unither Manufacturing LLC has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.

Learn More
Notice 1 May 2025 regulatory compliance, pharmaceutical industry, dea, controlled substances, drug enforcement

💊Importer of Controlled Substances Application by US Pharmacopeial Convention

United States Pharmacopeial Convention has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.

Learn More
Notice 28 Apr 2025 compliance, pharmaceutical industry, clinical trials, controlled substances, drug enforcement

💊Almac Clinical Services' Importer Application for Controlled Substances

Almac Clinical Services, Inc., (ACSI) has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.

Learn More
Notice 28 Apr 2025 regulatory compliance, business operations, controlled substances, drug enforcement, import permits

🚨Lipomed's Application for Importing Controlled Substances Notice

Lipomed has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.

Learn More
Notice 28 Apr 2025 compliance, regulatory, controlled substances, drug enforcement, business registration

⚖️VHG Labs Controlled Substances Import Application Overview

VHG Labs DBA LGC Standards has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.

Learn More
Notice 25 Apr 2025 pennsylvania, business compliance, pharmacy regulations, dea, controlled substances, drug enforcement

💊DEA Revokes Registrations of Multiple Pennsylvania Pharmacies

The DEA issued an Order to Show Cause and Immediate Suspension of Registrations to several pharmacies, alleging violations related to the dispensing and recordkeeping of controlled substances. The findings indicate significant discrepancies in record management, endangering public health, and leading to potential revocation of their registration for the sale of drugs.

Learn More
Notice 25 Apr 2025 compliance, regulation, pharmaceuticals, controlled substances, drug enforcement, specgx llc

💊DEA Notice

SpecGx LLC has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.

Learn More
Notice 23 Apr 2025 compliance, healthcare, regulation, pharmaceuticals, dea, controlled substances, drug enforcement, business consequences

⚖️DEA Revocation Decision Impacting De Novo Services, LLC

The Drug Enforcement Administration (DEA) has issued an order revoking the registration of De Novo Services, LLC due to substantial violations in managing controlled substances and maintaining proper recordkeeping. The decision underscores the stringent compliance requirements enforced by federal regulations to protect public health and safety, highlighting the consequences of non-adherence.

Learn More
Notice 22 Apr 2025 compliance, healthcare, regulations, registration, dea, business risk, drug enforcement

⚖️DEA Decision on Svetlana Burtman

The Department of Justice's ruling on Svetlana Burtman highlights numerous violations of the Controlled Substances Act, including operating an unregistered practice and failing to maintain adequate records. This decision underscores the rigorous compliance requirements for healthcare providers regarding controlled substances. The ramifications may extend beyond individual practitioners, influencing broader regulatory practices in the healthcare industry.

Learn More